This Is MS Multiple Sclerosis Knowledge & Support Community

MediciNova Inc, a biopharmaceutical company, has received a Notice of Allowance from the US Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis.

Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.

A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1311

More info on ibudilast from MediciNova...

http://www.medicinova.com/html/research ... etoverview

also...

http://www.chemicalbook.com/ProductChem ... 945_EN.htm

Phosphodiesterase inhibitor (IC 50 values are 53, 35, 48, 12 and 10 mM for PDE Ia, II, III, IV and V respectively). Inhibits platelet aggregation and is an orally-active cerebral vasodilator, bronchodilator and antiallergic agent.

also...

About 111 articles on ibudilast listed on Pubmed (should make for some interesting reading).

http://www.ncbi.nlm.nih.gov/pubmed?term=ibudilast


NHE